Non Hodgkin's Lymphoma








Information Patients and the Public (19 links)
Non-Hodgkin's lymphoma
NHS ChoicesNHS Choices information is quality assured by experts and content is reviewed at least every 2 years. Further info.
Non-Hodgkin's lymphoma is the most common type of lymphoma in the UK, with more than 9,700 people diagnosed each year. An expert describes the symptoms, and Maureen talks about her experience of living with the disease.
Adult Non-Hodgkin Lymphoma Treatment
National Cancer InstitutePDQ summaries are written and frequently updated by editorial boards of experts Further info.
Cancer Research UKCancerHelp information is examined by both expert and lay reviewers. Content is reviewed every 12 to 18 months. Further info.
Cancer.NetContent is peer reviewed and Cancer.Net has an Editorial Board of experts and advocates. Content is reviewed annually or as needed. Further info.
Asociación Gerardo Alfaro A.C. - Español - Translate to English
A non-profit organization founded in 2007 to support and raise awareness of non-Hodgkin lymphoma (NHL).
France Lymphome Espoir | France Lymphoma Hope - Français - Translate to English
High-grade non-Hodgkin lymphoma
Lymphoma Association
online booklet (PDF)
Low-grade non-Hodgkin lymphoma
Lymphoma Association
online booklet (PDF)
LymfklierkankerVereniging Nederland - Nederlands - Translate to English
Society founded in 1978 to support patients and their families who are dealing with lymphoma.
A registered charity in the UK formed in 1987 which provides information and support for people with lymphoma and also supports health professionals. The Association runs a UK telephone helpline, chat rooms and the Website includes information for both patients and health professionals.
The Foundation, founded in 1998, focuses on lymphoma research, education and awareness in Canada.
A non-profit national organization devoted exclusively to funding innovative lymphoma research and providing people with lymphoma and healthcare professionals with up-to-date information.
A UK registered charity which supports research into the treatment of lymphoma. It makes grants to medical researchers at the Lymphoma Trials Office who organise clinical trials and operate a database containing details of over 19,600 patients.
Non-Hodgkin lymphoma statistics
Cancer Research UK
Statistics for the UK, including incidence, mortality, survival, risk factors and stats related to treatment and symptom relief.
American Cancer Society
Detailed questions and answers
NHS Choices
Non-Hodgkin's Lymphomas Support Group
ACOR
Email discussion list
The central nervous system and lymphoma
Lymphoma Association
Detailed information about the central nervous system and how it can be affected by lymphoma - both lymphoma starting in the CNS or lymphoma that has spread to the CNS. (PDF)
What You Need To Know About - Non-Hodgkin Lymphoma
National Cancer Institute
Detailed booklet
Information for Health Professionals / Researchers (11 links)
- PubMed search for publications about Non-Hodgkin Lymphoma - Limit search to: [Reviews]
PubMed Central search for free-access publications about Non-Hodgkin Lymphoma
MeSH term: Lymphoma, Non-HodgkinUS National Library of Medicine
PubMed has over 22 million citations for biomedical literature from MEDLINE, life science journals, and online books. Constantly updated.
Adult Non-Hodgkin Lymphoma Treatment
National Cancer InstitutePDQ summaries are written and frequently updated by editorial boards of experts Further info.
Patient UKPatientUK content is peer reviewed. Content is reviewed by a team led by a Clinical Editor to reflect new or updated guidance and publications. Further info.
Case study: An eighty-one year old woman with follicular center cell lymphoma
Department of Pathology, University of Pittsburgh
Clinical Trials - Non-Hodgkin Lymphoma, adult
National Cancer Institute
Search of the NCI's database of 12,000+ clinical trials from around the world.
Oncolex - Oslo University Hospital (Norway) and MD Andersen (USA)
Detailed reference article covering etiology, histology, staging, metastatic patterns, symptoms, differential diagnoses, prognosis, treatment and follow-up.
Non-Hodgkin lymphoma statistics
Cancer Research UK
Statistics for the UK, including incidence, mortality, survival, risk factors and stats related to treatment and symptom relief.
SEER Stat Fact Sheets: B-cell Non-Hodgkin Lymphoma
SEER, National Cancer Institute
Overview and specific fact sheets on incidence and mortality, and survival and stage.
SEER Stat Fact Sheets: Non-Hodgkin Lymphoma
SEER, National Cancer Institute
Overview and specific fact sheets on incidence and mortality, survival and stage,
lifetime risk, and prevalence.
SEER Stat Fact Sheets: T-cell Non-Hodgkin Lymphoma
SEER, National Cancer Institute
Overview and specific fact sheets on incidence and mortality, and survival and stage.
Latest Research Publications
This list of publications is regularly updated (Source: PubMed).
Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality.
Anticancer Res. 2017; 37(2):813-817 [PubMed] Related Publications
PATIENTS AND METHODS: We utilized the Surveillance Epidemiology and End Results (SEER) 18 database to extract data on patients with gDLBCL diagnosed between 1983-2012. Primary site-specific cancer-directed surgery using SEER site-specific surgical codes and annual trends were analyzed. Patients were analyzed before and after 2006, the year rituximab gained U.S. Food and Drug Administration approval.
RESULTS: Joinpoint trend analysis showed the sharpest decline in surgical rates between 2000-2010. Adjusted surgical rates computed using poisson regression declined from 54.4% in 1983 to 6.9% in 2012, with an annual percentage change of -8.9% (95% confidence interval=-9.7% to -8.3%; p-value <0.01). No significant mortality increase at 30 and 60 days was found.
CONCLUSION: While rituximab appears to have significantly changed how surgery is utilized for patients with gDLBCL, early mortality was unchanged.
Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: A retrospective study of 29 case reports.
Medicine (Baltimore). 2017; 96(5):e5985 [PubMed] Free Access to Full Article Related Publications
CONCLUSION: Unlike European studies on "classical" IVL, our study showed that the French Canadian presentation of this subtype of IVL is more frequently observed with neurological rather than cutaneous involvement. Finally, an early diagnosis is of primary importance since almost a quarter of patients receive a post-mortem diagnosis. A prompt diagnosis allows the introduction of an early treatment, associated with a CR in 53% of patients.
Non-Hodgkin's lymphoma involving a femur bone and bilateral adrenal glands alone with adrenal insufficiency.
BMJ Case Rep. 2017; 2017 [PubMed] Related Publications
An unusual case of Epstein-Barr virus-positive large B-cell lymphoma lacking various B-cell markers.
Diagn Pathol. 2017; 12(1):15 [PubMed] Free Access to Full Article Related Publications
CASE PRESENTATION: An 83-year-old man presented with a submandibular tumor. Histology of a lymph node biopsy specimen revealed diffuse proliferation of centroblast- or immunoblast-like lymphoid cells with plasmacytic differentiation. Scattered Hodgkin/Reed-Sternberg-like cells were also visible. A routine immunohistochemistry antibody panel revealed that the tumor cells were negative for B-cell and T-cell markers (i.e., CD3, CD19, CD20, CD38, CD45RO, CD79a, CD138, and Pax-5), but were positive for CD30 and MUM-1, not defining the lineage of tumor cells. The final diagnosis of EBV-positive DLBCL was confirmed based on the expression of B-cell-specific transcription factors (Oct-2 and BOB.1), PCR-based identification of monoclonal rearrangement of the immunoglobulin genes, and the presence of EBV-encoded small RNAs in the tumor cells (identified using in situ hybridization).
CONCLUSION: The downregulation of broad band of B-cell markers in the present case with EBV-positive DLBCL posed a diagnostic dilemma, as the possible diagnoses included differentiation from anaplastic large cell lymphoma and CD20-negative B-cell lymphomas. Results of immunohistochemical panel including B-cell-specific transcription factors and gene rearrangement analyses critically support the correct diagnosis.
Zosteriform Mycosis Fungoides: A New Clinical Presentation With a Dermatomal Distribution.
Am J Dermatopathol. 2017; 39(2):e17-e18 [PubMed] Related Publications
Primary Cutaneous Follicular Helper T-cell Lymphoma in a Patient With Neurofibromatosis Type 1: Case Report and Review of the Literature.
Am J Dermatopathol. 2017; 39(2):134-139 [PubMed] Related Publications
Primary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with multiple pure ground-glass opacities: a case report.
J Cardiothorac Surg. 2017; 12(1):2 [PubMed] Free Access to Full Article Related Publications
CASE PRESENTATION: A 35-year-old woman was found to have a few shadows with ground glass opacities on chest computed tomography (CT) in 2012. A shadow in right S10 that was initially very small increased in size over time, and was 14 × 8 mm in 2015. Other shadows also appeared. Because lung adenocarcinoma was suspected, the patient underwent video-assisted thoracoscopic surgery with a right wedge resection of the lower lobe that included the largest nodule in S10 and other nodules. Histopathological examination of the right S10 and other lesions revealed small- or medium-sized lymphocyte-like cells that were located in the alveolar interseptal spaces. The alveolar walls remained intact. Immunohistochemical staining showed that tumor cells were positive for CD20, CD79a, and BCL2 expression. The lesions were diagnosed as extranodal marginal zone B-cell lymphoma of MALT.
CONCLUSIONS: We think that the ground glass opacities on CT were accounted for by MALT lesions that contained intact alveolar air spaces. The patient has remained well during 12 months of follow up after surgery. Although she did not receive chemotherapy because the MALT lymphoma lesions have been stable without progression, the patient is kept under close observation because of potential progression of the disease.
Pancreatic lymphoma complicating early stage chronic hepatitis C.
BMJ Case Rep. 2017; 2017 [PubMed] Related Publications
Donor-derived mycosis fungoides following reduced intensity haematopoietic stem cell transplantation from a matched unrelated donor.
BMJ Case Rep. 2017; 2017 [PubMed] Free Access to Full Article Related Publications
Prognostic efficacy of the human B-cell lymphoma prognostic genes in predicting disease-free survival (DFS) in the canine counterpart.
BMC Vet Res. 2017; 13(1):17 [PubMed] Free Access to Full Article Related Publications
METHODS: The corresponding probe sets of 36 human B-cell lymphoma prognostic genes were retrieved from 2 canine B-cell lymphoma microarray datasets (GSE43664 and GSE39365) (76 samples), and prognostic probe sets were thereafter detected using the univariate and multivariate Cox proportional-hazard model and the Kaplan-Meier analysis. The two datasets were employed both as training sets and as external validation sets for each other. Results were confirmed using quantitative real-time PCR (qRT-PCR) analysis.
RESULTS: In the univariate analysis, CCND1, CCND2, PAX5, CR2, LMO2, HLA-DQA1, P53, CD38, MYC-N, MYBL1, and BIRCS5 were associated with longer disease-free survival (DFS), while CD44, PLAU, and FN1 were allied to shorter DFS. However, the multivariate Cox proportional-hazard analysis confirmed CCND1 and BIRCS5 as prognostic genes for canine B-cell lymphoma. qRT-PCR used for verification of results indicated that expression level of CCND1 was significantly higher in B-cell lymphoma patients with the long DFS than ones with the short DFS, while expression level of BIRCS5 wasn't significantly different between two groups.
CONCLUSION: Our results confirmed CCND1 as important gene that can be used as a potential predictor in this tumor type.
Primary non-Hodgkin's lymphoma of the tongue: a diagnostic dilemma of unusual case presentation.
BMJ Case Rep. 2017; 2017 [PubMed] Related Publications
First reported case of disseminated Nocardia kroppenstedtii sp nov. infection presenting with brain abscess and endocarditis in an immunocompromised patient with mantle cell lymphoma: challenges in diagnosis and treatment.
BMJ Case Rep. 2017; 2017 [PubMed] Related Publications
Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma.
Diagn Pathol. 2017; 12(1):3 [PubMed] Free Access to Full Article Related Publications
METHOD: Clinical and morphological reviews of 120 cases diagnosed with diffuse large B-cell lymphoma and Burkitt lymphoma were conducted. Immunohistochemistry (CD20, CD79a, PAX5, CD10, Bcl6, Bcl2, MUM1, TDT and Myc) and fluorescence in situ hybridization for detection of MYC, BCL2 and BCL6 gene translocations were performed in a tissue microarray platform.
RESULTS: Three cases of DHL were detected: two with translocations of MYC and BCL2 and one with translocations of MYC and BCL6, all leading to death in less than six months. Among 90 cytogenetically evaluable biopsies, associations were determined between immunohistochemistry and fluorescence in situ hybridization for MYC (p = 0.036) and BCL2 (p = 0.001). However, these showed only regular agreement, indicated by Kappa values of 0.23 [0.0;0.49] and 0.35 [0.13;0.56], respectively. "Starry sky" morphology was strongly associated with MYC positivity (p = 0.01). The detection of three cases of DHL, all resulting in death, confirms the rarity and aggressiveness of this neoplasm.
CONCLUSIONS: The "starry sky" morphological pattern and immunohistochemical expression of Myc and Bcl2 represent possible selection factors for additional cytogenetic diagnostic testing.
Atypical femoral fracture as first sign of non-hodgkin lymphoma- case report with a brief review of the literature.
Clin Ter. 2016 Nov-Dec; 167(6):188-190 [PubMed] Related Publications
CONCLUSIONS: AFF can occur also in patients not treated with BPs. In the present case report, the cause of the fracture was a NHL. Even uncommon, this occurrence should be considered in the differential diagnosis of radicular pain.
Angioimmunoblastic T-cell Lymphoma Associated with IgA Nephropathy.
Intern Med. 2017; 56(1):85-89 [PubMed] Free Access to Full Article Related Publications
Expression of LEF1 in mantle cell lymphoma.
Ann Diagn Pathol. 2017; 26:57-59 [PubMed] Related Publications
Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.
Ann Diagn Pathol. 2017; 26:16-22 [PubMed] Related Publications
Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Ann Hematol. 2017; 96(3):405-410 [PubMed] Related Publications
MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis.
Cancer Genomics Proteomics. 2017; 14(1):75-82 [PubMed] Free Access to Full Article Related Publications
MATERIALS AND METHODS: We analyzed the expression of 384 miRNAs using TaqMan microRNA assay in a training series of 10 gastric MALT lymphomas, 3 chronic gastritis and 2 reactive lymph nodes. Then, significantly deregulated miRNAs were individually assessed by real-time PCR in a validation series of 16 gastric MALT lymphomas and 12 chronic gastritis.
RESULTS: Gastric MALT lymphoma is characterized by a specific miRNA expression profile. Among the differentially expressed miRNAs, a significant overexpression of miR-142-3p and miR-155 and down-regulation of miR-203 was observed in gastric MALT lymphoma when compared to chronic gastritis.
CONCLUSION: miR-142-3p, miR-155 and miR-203 expression levels might be helpful biomarkers for the differential diagnosis between gastric MALT lymphomas and chronic gastritis.
CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma.
Am J Clin Pathol. 2016; 146(6):747-752 [PubMed] Related Publications
METHODS: Biopsy specimens were evaluated using Wright-Giemsa-stained or H&E-stained sections, flow cytometry, immunohistochemistry, conventional cytogenetic, next-generation sequencing, and fluorescence in situ hybridization.
RESULTS: The patient continued to be refractory to intensive chemotherapy and radiation therapy. Initial conventional cytogenetic analysis showed a complex karyotype with amplification of the CCND1-IGH fusion gene on the der(14): 44, Y, t(X;2)(p22.3;q21), del(2)(p21), del(6)(p23), add(7)(p22),-9, del(9)(p22), add(11)(q13),-13, add(14)(p11.2), der(14)t(11;14)(q13;q32)hsr(14)(q32), add(18)(q23), add(21)(p11.1),-22,+mar[12]. A repeat biopsy revealed MCL, pleomorphic variant, with loss of CD5 expression and extra copies of the MYC CONCLUSIONS: CCND1-IGH fusion-amplification with MYC copy number gain is extremely rare and may play a role in disease progression in a subset of MCL cases.
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.
Crit Rev Oncol Hematol. 2017; 109:42-50 [PubMed] Article available free on PMC after 01/01/2018 Related Publications
OBJECTIVE: Perform a systematic review on the use of BV in non-Hodgkin lymphoma (NHL) and other CD30(+) malignancies in humans.
DATA SOURCES: We searched various databases including PubMed (1946-2015), EMBASE (1947-2015), and Cochrane Central Register of Controlled Trials (1898-2015).
ELIGIBILITY CRITERIA: Inclusion criteria specified all studies and case reports of NHLs in which BV therapy was administered.
INCLUDED STUDIES: A total of 28 articles met these criteria and are summarized in this manuscript.
CONCLUSION: Our findings indicate that BV induces a variety of responses, largely positive in nature and variable between NHL subtypes. With additional, properly powered prospective studies, BV may prove to be a strong candidate in the treatment of various CD30(+) malignancies.
Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis.
Acta Med Okayama. 2016; 70(6):503-506 [PubMed] Related Publications
Anaplastic large cell lymphoma masquerading as osteomyelitis of the shoulder: an uncommon presentation.
BMJ Case Rep. 2016; 2016 [PubMed] Related Publications
Prognostic Importance of Bone Marrow Uptake on Baseline (18)F-FDG Positron Emission Tomography in Diffuse Large B Cell Lymphoma.
Cancer Biother Radiopharm. 2016; 31(10):361-365 [PubMed] Related Publications
MATERIALS AND METHODS: Fifty-four (mean age: 55.5 ± 18.3 years, 20 female and 34 male) DLBCL patients who underwent pretreatment (18)F-FDG PET/CT were included to the study. Focal or diffuse BM (18)F-FDG uptake that is higher than mediastinal blood pool uptake was accepted as positive. After staging of disease by CT and (18)F-FDG PET/CT, all the patients received R-CHOP treatment after diagnostic blinded bone marrow biopsy (BMB). Presence of positive BM uptake in (18)F-FDG PET/CT and histopathological examination results of BMBs were analyzed by Chi-square test. Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) of (18)F-FDG PET/CT in the detection of BM involvement were calculated. Prognostic importance of the presence of BM (18)F-FDG uptake was analyzed by Kaplan-Meier analysis.
RESULTS: BM (18)F-FDG uptake was detected in 8 patients. Histopathological examination of BMB revealed BM involvement in 6 out of 8 patients. BMB was negative in all patients who have no (18)F-FDG uptake in the evaluation of PET/CT images. Sensitivity, specificity, accuracy, PPV, and NPV of (18)F-FDG PET/CT in the detection of BM involvement were calculated as 100%, 96%, 96%, 75%, and 100%, respectively. In the Kaplan-Meier analysis, we found that presence of pretreatment (18)F-FDG uptake in BM has a prognostic importance. Whereas mean time to progression (TTP) in patients with BM uptake was 32.25 ± 10.9 months and mean TTP in those without was 51.69 ± 3.6 months (p = 0.013).
CONCLUSIONS: BM uptake in pretreatment (18)F-FDG PET/CT is an important prognostic factor in DLBCL patients. Moreover, in consideration of high NPV, (18)F-FDG PET/CT could eliminate unnecessary BMB in FDG-negative patients.
Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report.
Diagn Pathol. 2016; 11(1):137 [PubMed] Article available free on PMC after 01/01/2018 Related Publications
CASE PRESENTATION: A 53-year old man presented to our Dermatology Clinic due to a 1-year history of generalized itching, fatigue of 2-3 month's duration, nausea and mid back rash that was biopsied. PET (positron emission tomography)/CT (computed tomography) was performed and revealed inguinal, pelvic, retroperitoneal, axillary, and cervical lymphadenopathy. The patient was referred to surgery for excisional biopsy of a right inguinal lymph node. Diagnostic H&E stained slides and ancillary studies were reviewed for the lymph node and skin specimens. B-cell clonality by PCR and sequencing studies were performed on both specimens. We demonstrate that this patient's MZL and DLBCL-IF are clonally related, strongly suggesting that transformation of MZL to DLBCL had occurred. Furthermore, we identified a novel deletion of the long arm of chromosome 20 (del(20q12)) and a missense mutation in BIRC3 (Baculoviral IAP repeat-containing protein 3) in this patient's DLBCL that are absent from his MZL, suggesting that these genetic alterations contributed to the large cell transformation.
CONCLUSIONS: To our knowledge, this is the first report providing molecular evidence for a previously suspected link between MZL and DLBCL-IF. In addition, we describe for the first time del(20q12) and a missense mutation in BIRC3 in DLBCL. Our findings also raise awareness of DLBCL-IF and discuss the diagnostic pitfalls of this rare entity.
Genetic characteristics of non-Hodgkin lymphoma in ethnic Uighur people, and their clinical significance.
Genet Mol Res. 2016; 15(4) [PubMed] Related Publications
Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20.
Chemotherapy. 2017; 62(2):140-146 [PubMed] Related Publications
Primary central nervous system ALK-positive anaplastic large cell lymphoma in an adult: A rare case report.
Medicine (Baltimore). 2016; 95(49):e5534 [PubMed] Article available free on PMC after 01/01/2018 Related Publications
PATIENT CONCERNS: We report a 34-year-old Chinese male patient who presented with headache, diplopia, and vomit. Cerebrospinal fluid (CSF) analysis via lumbar puncture showed elevated CSF pressure, elevated CSF protein concentrations, decreased CSF glucose and chloride concentration significantly, and pleocytosis of 68 to 350 × 10/L, in which lymphocytes and monocytes were predominant. These changes could be suggestive of tuberculous (TB) meningitis. Enhanced magnetic resonance imaging of spinal cord delineated multiple enhancing nodules in spinal cord, cauda equina, and cristae membrane, and multiple abnormal enhancing lesions in bilateral lumbar intervertebral foramen.
DIAGNOSES: Spinal dura mater biopsy and paraffin pathology examination revealed anaplastic lymphoma kinase positive ALCL.
INTERVENTIONS: High-dose methotrexate, cytosine arabinoside craniospinal, and radiotherapy.
OUTCOMES: Last follow-up on September 22, 2015 showed no evidence of tumor recurrence and the lower extremity muscle strength recovered to 4/5.
LESSONS: ALCL of primary central nervous system is an exceedingly rare tumor, which is usually misdiagnosed as meningitis (especially TB meningitis) according to clinical manifestation and laboratory examination. Thus closely monitoring patient's conditions and timely adjusting therapeutic regimen during treatment are necessary.
Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment.
Ann Hematol. 2017; 96(3):411-420 [PubMed] Related Publications
Plasmablastic lymphoma mimicking carcinomatosis: A case report and review of the literature.
Diagn Cytopathol. 2017; 45(3):243-246 [PubMed] Related Publications